More News

06 Dec 2022 AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
01 Dec 2022 Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
01 Dec 2022 BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
30 Nov 2022 Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
29 Nov 2022 Envisagenics Announces Research Collaboration with Bristol Myers Squibb
29 Nov 2022 BigHat Biosciences Announces Research Collaboration with Merck
29 Nov 2022 Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim
29 Nov 2022 C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
29 Nov 2022 AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
21 Nov 2022 Merck to Acquire Imago BioSciences, Inc.
17 Nov 2022 Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
15 Nov 2022 Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases
14 Nov 2022 Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
14 Nov 2022 Ionis partners with Metagenomi to add gene editing to its broad technology platform
13 Nov 2022 Emerging Novel RNA-Targeted Drug Modalities Open the Door for Novel Treatments
10 Nov 2022 Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
04 Nov 2022 Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
01 Nov 2022 Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets
30 Oct 2022 PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas
27 Oct 2022 2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
27 Oct 2022 CSL enters into Strategic Option and License Agreement with Translational Sciences
26 Oct 2022 Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
26 Oct 2022 Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
26 Oct 2022 Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
25 Oct 2022 Syncona to Acquire Applied Genetic Technologies Corporation

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up